.
AVXL financial statements
* Numbers in thousands
Year |
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
Capitalization * |
28 450 | 16 592 | 6 793 | 196 627 | 104 054 | 169 899 | 106 727 | 135 960 | 343 350 | 1 322 848 | 774 367 |
EV * |
28 738 | 16 458 | 5 443 | 181 422 | 94 867 | 142 458 | 83 797 | 113 774 | 314 101 | 1 170 741 | 1 170 741 |
Stock price $ |
4.04 | 2.08 | 0.684 | 10.58 | 2.96 | 4.16 | 2.39 | 2.78 | 5.9 | 18.74 | 10.97 |
Number of shares * |
7 042 | 7 977 | 9 932 | 18 585 | 35 153 | 40 841 | 44 656 | 48 906 | 58 195 | 70 590 | 70 590 |
EPS |
-1,18 | -0,46 | -1,14 | -0,65 | -0,42 | -0,33 | -0,39 | -0,54 | -0,45 | -0,53 | -0,53 |
Revenue * |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income * |
-8 302 | -3 700 | -11 368 | -12 108 | -14 737 | -13 460 | -17 453 | -26 295 | -26 281 | -37 374 | -37 374 |
Operating profit * |
-4 316 | -2 133 | -2 969 | -7 109 | -14 877 | -15 539 | -19 185 | -28 808 | -30 938 | -37 641 | -37 641 |
Total liabilities * |
2 888 | 2 857 | 7 161 | 2 661 | 3 191 | 3 584 | 3 885 | 5 040 | 7 306 | 10 798 | 10 798 |
Net debt * |
288 | -134 | -1 350 | -15 205 | -9 187 | -27 440 | -22 931 | -22 186 | -29 249 | -152 108 | -152 108 |
Total assets * |
13 | 393 | 7 354 | 15 470 | 9 499 | 27 838 | 24 376 | 25 329 | 34 542 | 161 616 | 161 616 |
Equity * |
-2 875 | -2 463 | 193 | 12 809 | 6 308 | 24 254 | 20 492 | 20 290 | 27 237 | 150 818 | 150 818 |
Cash and investments * |
11 | 345 | 7 262 | 15 291 | 9 187 | 27 440 | 22 931 | 22 186 | 29 249 | 152 108 | 152 108 |
Over the past 10 years, the maximum capitalization of Anavex Life Sciences Corp. is 1 322 848, the minimum is 6 793. Maximum net income 0, Minimum net income -37 374. The maximum price of AVXL shares is 18.74, the minimum price is 0.684.
.
AVXL valuation
Year |
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-3,43 | -4,48 | -0,60 | -16,24 | -7,06 | -12,62 | -6,11 | -5,17 | -13,06 | -35,40 | -20,72 |
P/B |
-9,90 | -6,74 | 35,27 | 15,35 | 16,50 | 7,00 | 5,21 | 6,70 | 12,61 | 8,77 | 5,13 |
P/S |
0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
E/P |
-29% | -22% | -167% | -6% | -14% | -8% | -16% | -19% | -8% | -3% | -5% |
P/FCF |
-16,81 | -21,34 | -2,55 | -46,52 | -11,27 | -18,84 | -8,48 | -7,34 | -16,13 | -43,54 | -25,49 |
.
AVXL profitability
Year |
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
ROE |
289% | 150% | -5 902% | -95% | -234% | -56% | -85% | -130% | -96% | -25% | |
ROA |
-63 116% | -940% | -155% | -78% | -155% | -48% | -72% | -104% | -76% | -23% | |
ROIC |
150% | 137% | -50% | -56% | -236% | -64% | -94% | -142% | -114% | -24% |